Major Players - Stem Cells Industry

Over the course of the projection period, the approval and introduction of new products is anticipated to fuel market expansion for stem cells worldwide. For instance, the Israeli Patent Office granted BioRestorative Therapies, Inc.'s patent application for a process of producing brown fat stem cells in December 2019.

Additionally, more stem cell banking resource centres are anticipated to support market expansion. For instance, the Jerudong Park Medical Centre in Brunei now has a Stem Cell Banking Resource Centre thanks to Stemlife Berhad, a Malaysian cord blood bank.

According to estimates, the market for  Stem Cells would be worth US$ 9,941.2 million in 2020 and US$ 18,289.9 million by the end of 2027.

Key Companies in the Stem Cells Industry:

Advanced Cell Technology, Inc.:

1. Sapporo, Japan-based developer of cell preservation and regenerative medicine-related businesses. Through collaboration with pharmaceutical companies and research institutions like the National University Corporation Gifu University, the company offers regenerative medicine that uses preserved cells to help patients' dental pulp cells. Established in 2008. Head office in Japan.

Angel Biotechnology Holdings PLC:

2. Tokyo, Japan-based Angel Bridge is an angel network that was established in 2015. The company wants to invest in technology-related early-stage businesses.

Lineage Cell Therapeutics:

3. A biotechnology firm in the clinical stages, Lineage Cell Therapeutics Inc. is dedicated to the creation and marketing of cutting-edge treatments for the treatment of degenerative diseases. Cell replacement and cell/drug delivery are two platform technologies that are the foundation of the company's pipeline. The business, which has its headquarters in Carlsbad, California, was established on November 30, 1990 by Judith Segall, Hal Sternberg, Paul E. Segall, and Harold D. Waitz. Lineage and Genentech Form an Exclusive Global Partnership to Develop and Market OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders.

BrainStorm Cell Therapeutics, Inc.:

4. Established in 2000. Head offices in the United States. The biotech firm Brainstorm Cell Therapeutics Inc. For crippling neurodegenerative diseases such Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's illness), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD), the business is exploring revolutionary adult stem cell therapies. BrainStorm Cell Therapeutics releases financial results for the second quarter of 2022 and offers a corporate update.

California Stem Cell Inc.:

5. California Stem Cell Inc.: High-purity human cells are produced for use in research and clinical trials. The business provides stem cell culture medium, including serum-free media for the growth of human embryonic stem cells (hESC), serum-free media for the growth of human myoblasts, and serum-free media formulation for the growth of hESC for lab research. Founded in 2005. United States headquarters. Declaratory Agreement for the Purchase of California Stem Cell, Inc. by NeoStem announced.

Celgene Corporation:

6. Creator of biologic medications for the treatment of inflammatory, immunological, and cancerous disorders. The business sells medications to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma, as well as a less harmful thalidomide derivative. Founded 1986. Bristol-Myers Squibb will buy Celgene and establish a premier, innovative biopharma company there.

Takara Bio Europe AB:

7. The biotechnology firm Takara Bio Inc. creates methods for gene therapy. Bioindustry, Gene Therapy, and AgriBio are the three business segments that the corporation reports on. The bioindustry division of Takara offers universities and businesses all around the world with scientific equipment, research reagents, and numerous contracted services. Established in 2002. Head office in Japan.

Definition:

Stem cells are special human cells that are able to develop into many different cell types.